Table 3.
Pharmacological Therapy for Wilson’s Disease
Drug | Mode of Action | Maintenance Dose | Side effects |
---|---|---|---|
Trientine | Induction of urinarycopper excretion by chelating action | 750-1,000 mg/day three times a day; children, 20-25 mg/kg/day | Gastritis, in rare cases aplastic anemia and sideroblastic anemia, neurological deterioration during initial phase of treatment (about 26% [130]) |
D-Penicillamine | Induction of urinary copper excretion by chelating action | 750-1,000 mg/day three times a day; children: 20 mg/kg/day | Fever, rash, proteinuria, lupus-like reation, aplastic anemia, leukopenia, thrombocytopenia, nephrotic syndrome, degenerative change in skin, elastosis perforans serpingosa, serous retinitis, hepatotoxicity, neurological deterioration during initial phase of treatment (about 50% [110]) |
Zinc | Blockage of copper absorption by inducing metallothionein in enterocytes | 150 mg/day, three times a day; children: 50-75 mg/day | Gastritis, biochemical pancreatitis, zinc accumulation, possible changes in immune function |
Tetrathiomolybdate | Detoxifying copper in plasma and blocking copper absorption by complexation with copper | 20 mg, three times with meals and three times between meals [108] | Anemia, neutropenia, hepatotoxicity, neurologic deterioration during initial treatment (about 4% [108]) |